Degenerative bone or joint disease treatment compsn. - contg. benzo-pyrone or dobesilate calcium, esp. for treating osteo-arthrosis or podotrochlosis

摘要

Human or veterinary medicinal compsn. for treatment or prophyl axis of bone and joint diseases associated with the "compartment syndrome" contains benzopyrone (I) or dobesilate calcium (II) as active agent. USE/ADVANTAGE - (I) and (II) combat the compartment syndrome, i.e. painful conditions associated with increased internal pressure (due to circulatory disorders) in tissues which cannot swell to relieve the pressure, by stabilising capillary walls, reducing pressure by protein resorption and normalising microcirculation. (I) and (II) are useful for causal therapy of degenerative joint disorders, esp. osteoarthrosis in humans or animals or podotrochlosis in horses. Daily oral dose of 5,6-alpha-benzopyrone is 2-4mg/kg in humans or dogs is 0.5-1mg/kg in horses. Daily oral dose of (II) in humans or dogs is 10-20mg/kg. Treatment is usually for 2-4 weeks. Recurrence is rarely observed. (I) has previously been used for reducing oedema and (II) for stopping bleeding.